182 related articles for article (PubMed ID: 33527340)
1. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Ataga KI; Staffa SJ; Brugnara C; Stocker JW
Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340
[No Abstract] [Full Text] [Related]
2. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
3. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
4. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
5. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
Ataga KI; Stocker J
Expert Opin Investig Drugs; 2009 Feb; 18(2):231-9. PubMed ID: 19236269
[TBL] [Abstract][Full Text] [Related]
6. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
8. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Ershler WB; Holbrook ME
Transfusion; 2020 Dec; 60(12):3066-3067. PubMed ID: 32815179
[No Abstract] [Full Text] [Related]
9. Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.
Castro OL; Gordeuk VR; Gladwin MT; Steinberg MH
Br J Haematol; 2011 Dec; 155(5):636-8. PubMed ID: 21732927
[No Abstract] [Full Text] [Related]
10. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
Minniti CP; Knight-Madden J; Tonda M; Gray S; Lehrer-Graiwer J; Biemond BJ
Am J Hematol; 2021 Apr; 96(4):E126-E128. PubMed ID: 33476432
[No Abstract] [Full Text] [Related]
11. Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.
Minniti CP; Wilson J; Mendelsohn L; Rigdon GC; Stocker JW; Remaley AT; Kato GJ
Br J Haematol; 2011 Dec; 155(5):634-6. PubMed ID: 21651507
[No Abstract] [Full Text] [Related]
12. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
13. Investigational agents for sickle cell disease.
Okpala I
Expert Opin Investig Drugs; 2006 Aug; 15(8):833-42. PubMed ID: 16859388
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
15. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
16. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD003426. PubMed ID: 30338520
[TBL] [Abstract][Full Text] [Related]
17. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
18. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2016 Mar; 3():CD003426. PubMed ID: 26942338
[TBL] [Abstract][Full Text] [Related]
19. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2012 Jul; (7):CD003426. PubMed ID: 22786485
[TBL] [Abstract][Full Text] [Related]
20. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
